PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 22 of 32 · 745 questions tagged clinical-trials.

745 questions · sorted by votes · page 22 of 32

13 votes3 answers12k views
What is the reported incidence of headache on semaglutide in STEP 4?

Conditions: headache · semaglutide · STEP 4. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by pierce_count 24k · 2.1 years ago
13 votes 4 answers11k views
What is the reported incidence of vomiting on tirzepatide in SURMOUNT-4?

Details up front: vomiting · tirzepatide · SURMOUNT-4. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by fill_volume 22k · 17 months ago
13 votes 4 answers11k views
What did SURMOUNT-2 do with participants who could not tolerate a step?

My records go back to the first dose with dates, so I can reconstruct the timeline exactly. I have read the primary source rather than the summary, which has left me…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by bac_or_bust 33k · 13 months ago
13 votes 5 answers9.3k views
Is STEP 1 a fair comparison of semaglutide against its comparator arm?

The case in front of me: STEP 1 · semaglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by deamidation_watch 45k · 3 months ago
13 votes5 answers8.5k views
What does PIONEER-4 tell me about nausea at the 25 mg dose?

Numbers first: PIONEER-4 · nausea · 25 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by meniscus_film 32k · 15 months ago
13 votes0 answers8.1k views
What is the reported incidence of nausea on orforglipron in ATTAIN-1?

Setup, so nobody has to ask: nausea · orforglipron · ATTAIN-1. I have read the primary source rather than the summary, which has left me with more questions. I…

nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by samir_bennani 15k · 22 months ago
13 votes 4 answers8k views
What does the mechanism of semaglutide predict that STEP 2 did not test?

For reference: semaglutide · STEP 2. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have tried to reason…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by retest_please 9.7k · 7 months ago
13 votes 5 answers6.9k views
What did the placebo arm of SELECT report for dizziness?

Concretely: SELECT · dizziness. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do not…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
asked by kofi_mensah 18k · 5 months ago
13 votes0 answers6.4k views
How comparable are mazdutide and semaglutide on the evidence available?

Details up front: mazdutide · semaglutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by second_lot 9.4k · 17 months ago
13 votes 5 answers5.7k views
What did SURMOUNT-4 do with participants who could not tolerate a step?

This came up because two published schedules for the same agent differ. I would like help reading this properly rather than being told what conclusion to reach. I…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by rune_thoresen 16k · 5 months ago
13 votes 5 answers4.6k views
How is an eGFR slope endpoint defined across a renal trial?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I would like help reading this properly rather than being told…

renal-outcomes
renal-outcomes

Kidney endpoints: the FLOW composite, eGFR slope as an endpoint, albuminuria regression, and why an early eGFR dip is expected rather than alarming.

9 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by mz_4113 101k · 30 days ago
13 votes 5 answers4.4k views
What does SURPASS-3 actually establish about tirzepatide?

What I am working with: SURPASS-3 · tirzepatide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by tenth_of_a_unit 57k · 5 months ago
13 votes4 answers3.8k views
How comparable are mazdutide and retatrutide on the evidence available?

Details up front: mazdutide · retatrutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by mass_shift_18 9.7k · 4 months ago
13 votes1 answer3.3k views
How comparable are tirzepatide and semaglutide on the evidence available?

Setup, so nobody has to ask: tirzepatide · semaglutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by seamus_brady 15k · 4 months ago
13 votes0 answers2.8k views
What does SURMOUNT-5 tell me about injection-site erythema at the 15 mg dose?

What I am working with: SURMOUNT-5 · injection-site erythema · 15 mg. I would like help reading this properly rather than being told what conclusion to reach. I have…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
injection-site-reaction
injection-site-reaction

Local reactions: erythema, induration, pruritus and nodules. Their relationship to injection depth, diluent composition, benzyl alcohol…

49 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by retest_please 9.7k · 3 months ago
12 votes 5 answers24k views
What did STEP 1 do with participants who could not tolerate a step?

I have been on a stable schedule for eleven weeks, so this is not a first-week question. This is presented as though it settles something, and I am not convinced it…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by swab_stopper 8.8k · 20 months ago
12 votes 5 answers19k views
How comparable are liraglutide and mazdutide on the evidence available?

What I am working with: liraglutide · mazdutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by sample_id 17k · 20 months ago
12 votes5 answers18k views
Is STEP 5 a fair comparison of semaglutide against its comparator arm?

The specifics, since they change the answer: STEP 5 · semaglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by ellis_thorne 17k · 19 months ago
12 votes5 answers18k views
What is the reported incidence of reflux on semaglutide in ESSENCE?

What I am working with: reflux · semaglutide · ESSENCE. This is presented as though it settles something, and I am not convinced it does. I have two documents that…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by sian_llewellyn 65k · 20 months ago
12 votes5 answers17k views
Why do two papers on SURMOUNT-2 report different headline figures?

I have the full paper rather than the abstract, and the supplementary appendix. I understand the observation; what I do not understand is the mechanism behind it. I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by ilaria_bertone 33k · 22 months ago
12 votes5 answers16k views
What does STEP 4 tell me about injection-site erythema at the 2 mg dose?

Stated plainly: STEP 4 · injection-site erythema · 2 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
injection-site-reaction
injection-site-reaction

Local reactions: erythema, induration, pruritus and nodules. Their relationship to injection depth, diluent composition, benzyl alcohol…

49 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by kelvin_lam 7.6k · 10 months ago
12 votes0 answers14k views
What did STEP 5 do with participants who could not tolerate a step?

I have been on a stable schedule for eleven weeks, so this is not a first-week question. This is presented as though it settles something, and I am not convinced it…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by second_lot 9.4k · 2.0 years ago
12 votes5 answers12k views
What does SUSTAIN-6 tell me about hair thinning at the 1 mg dose?

Details up front: SUSTAIN-6 · hair thinning · 1 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by kirsi_lahtinen 25k · 13 months ago
12 votes 5 answers11k views
How comparable are a GLP-1 receptor agonist and tirzepatide on the evidence available?

Numbers first: a GLP-1 receptor agonist · tirzepatide. I have used one of these for a while and I am considering switching, which requires a reason. What I care about…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by rune_thoresen 16k · 2.1 years ago